GlassScriptPhysician profile
Justin Michael Shepherd
NPI 1205340247
$2,626.08
in general payments reported to CMS, 2019-2025
18 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $420 · 2023: $655 · 2024: $588 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756 · Education: $32.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.77 |
| Education | $32.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $435.49 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $425.11 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $229.47 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $195.61 | 2024-2025 | |
| Dexcom, INC. | $181.85 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $177.87 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $149.56 | 2022-2024 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $145.38 | 2021-2022 | |
| Abbott Laboratories | $123.92 | 2021-2023 | Freestyle Libre 2 |
| Pfizer INC. | $113.86 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.96 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $71.77 | 2021-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $59.84 | 2024-2025 | Voquezna |
| Amgen INC. | $48.85 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $43.32 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.25 | 2021 | |
| Xeris Pharmaceuticals, INC. | $42.31 | 2022-2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $26.66 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.